belatacept

Home
Ligands
belatacept

GtoPdb Ligand ID: 6892

Synonyms: BMS-224818 | LEA29Y | Nulojix®

belatacept is an approved drug (FDA (2011), EMA (2011))

Compound class: Peptide or derivative

Comment: A recombinant protein fusing the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). CTLA-4 is essential for T-cell co-activation.
Belatecept differs from abatacept by only 2 amino acids.

View more information in the IUPHAR Pharmacology Education Project: belatacept

Summary
Biological activity
Clinical data
References
Structure
Similar ligands
Immunopharmacology

Immunopharmacology Comments
Approved for prophylaxis of organ rejection after kidney transplant.

Immunopharmacology Comments

Approved for prophylaxis of organ rejection after kidney transplant.

Immunopharmacology Disease
Disease	X-Refs	Comment	References
Allograft rejection		Approved drug for the prophylaxis of organ rejection after kidney transplant in EBV-exposed patients.